- Home
- ONVO vs REVB Comparison
ONVO vs REVB Comparison
Compare ONVO & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- REVB
- Stock Information
- Founded
- ONVO 2007
- REVB 2020
- Country
- ONVO United States
- REVB United States
- Employees
- ONVO N/A
- REVB N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ONVO Health Care
- REVB Health Care
- Exchange
- ONVO Nasdaq
- REVB Nasdaq
- Market Cap
- ONVO 3.0M
- REVB 2.8M
- IPO Year
- ONVO N/A
- REVB N/A
- Fundamental
- Price
- ONVO $1.87
- REVB $2.92
- Analyst Decision
- ONVO
- REVB
- Analyst Count
- ONVO 0
- REVB 0
- Target Price
- ONVO N/A
- REVB N/A
- AVG Volume (30 Days)
- ONVO 347.1K
- REVB 146.9K
- Earning Date
- ONVO 05-30-2025
- REVB 05-09-2025
- Dividend Yield
- ONVO N/A
- REVB N/A
- EPS Growth
- ONVO N/A
- REVB N/A
- EPS
- ONVO N/A
- REVB N/A
- Revenue
- ONVO $122,000.00
- REVB N/A
- Revenue This Year
- ONVO $59.08
- REVB N/A
- Revenue Next Year
- ONVO $18.24
- REVB N/A
- P/E Ratio
- ONVO N/A
- REVB N/A
- Revenue Growth
- ONVO N/A
- REVB N/A
- 52 Week Low
- ONVO $1.56
- REVB $2.36
- 52 Week High
- ONVO $21.96
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- ONVO 37.84
- REVB 45.77
- Support Level
- ONVO $1.56
- REVB $2.76
- Resistance Level
- ONVO $1.78
- REVB $3.62
- Average True Range (ATR)
- ONVO 0.24
- REVB 0.41
- MACD
- ONVO 0.13
- REVB 0.02
- Stochastic Oscillator
- ONVO 43.06
- REVB 34.12
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).